[The role of radiotherapy in the treatment of primary lymphoma of the brain. Presentation of the results of a series from the French Society of Neurosurgery and the literature].
One hundred eighty three patients (73.8%) in the SFNC series received radiation therapy alone, for 60 patients and with additional chemotherapy for 129 patients. From this review, a dose-response relationship with an improved survival time with doses greater than 50 Gy could not be demonstrated (p = 0.97). The multivariate risk analysis identified the radiation therapy as one of the factors which has the most favorable impact on survival. Radiation therapy remains the treatment method of choice. These results are compared with data from the literature.
Daban
A
A
Service de Radiothérapie, CHU, Poitiers.
Bataille
B
B
D001932:Brain Neoplasms / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D016371:Cranial Irradiation; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy*; D015999:Multivariate Analysis; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate